Clinical Trial Update: Safety, Efficacy and Pharmacokinetics of ALD403 [Phase 1]

View source ↗

Summary

Phase 1 study of ALD403 in migraine patients completed, reporting safety, efficacy signals, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• ALD403

Snippet

Sponsor: Alder Biopharmaceuticals, Inc. | Conditions: Migraine | Phase 1 | Status: COMPLETED